Antibiotice Ia (ATB) — Cash Flow-to-Debt Ratio
Antibiotice Ia (ATB) has a Cash Flow-to-Debt Ratio of 0.08x as of December 2025, meaning its operating cash flow of RON37.61 Million could theoretically repay 0% of its total liabilities (RON460.49 Million) in one year. See ATB free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Antibiotice Ia Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Antibiotice Ia across 4 annual periods. Also explore Antibiotice Ia net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Antibiotice Ia (2022–2025)
Year-by-year debt coverage analysis for Antibiotice Ia. For market capitalisation and broader financial context, see ATB stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (RON) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | RON72.44 Million | RON460.49 Million | ▼ -36.4% |
| 2024 | 0.25x | RON95.15 Million | RON384.95 Million | ▼ -41.0% |
| 2023 | 0.42x | RON122.46 Million | RON292.21 Million | ▼ -22.1% |
| 2022 | 0.54x | RON115.66 Million | RON215.04 Million | — |